文献速递炎症性肠病

炎症性肠病诊断时多维患者报告结局与生活质量:一项基于人群的起始队列研究

Multidimensional Patient-Reported Outcomes and Quality of Life at Diagnosis of IBD: A Population-Based Inception Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-10-24

该研究在哥本哈根炎症性肠病起始队列中,于2021年5月至2023年5月招募203例溃疡性结肠炎和116例克罗恩病患者,评估诊断时患者报告结局。诊断时分别有160例(78.8%)和99例(85.3%)报告至少1项中度至重度损害,89例(43.8%)和74例(63.8%)报告至少2项损害。结论为新诊断炎症性肠病患者存在显著患者报告疾病负担,强调临床实践中警惕性监测患者报告结局的重要性。

要点

  • 新诊断UC和CD患者中分别有78.8%和85.3%报告至少1项患者报告结局中度至重度损害。
  • 分别有43.8%和63.8%的UC和CD患者报告至少2项患者报告结局中度至重度损害(P<.01)。
  • 女性、UC病变范围和肠外表现与患者报告结局损害相关。

核心结论

  • 新诊断炎症性肠病患者存在显著患者报告疾病负担,强调临床实践中警惕性监测患者报告结局的重要性。

研究设计与样本

  • 前瞻性、基于人群的哥本哈根炎症性肠病起始队列研究,于2021年5月至2023年5月新诊断炎症性肠病患者中评估患者报告结局。
  • 共招募203例溃疡性结肠炎和116例克罗恩病患者,评估工具包括短炎症性肠病问卷、炎症性肠病残疾指数、慢性病治疗功能评估-疲劳量表和疾病活动相关患者报告结局。

主要发现

  • 诊断时,UC和CD患者分别有160例(78.8%)和99例(85.3%)报告至少1项患者报告结局中度至重度损害(P=.18)。
  • UC和CD患者分别有89例(43.8%)和74例(63.8%)报告至少2项患者报告结局中度至重度损害(P<.01)。
  • 女性、UC病变范围和肠外表现与患者报告结局损害相关,CD表型间未见差异。
  • UC中FACIT-F、IBD-DI和SIBDQ评分与Mayo内镜评分呈弱但显著相关,FACIT-F评分与C反应蛋白相关。
  • CD中SIBDQ、IBD-DI和FACIT-F与C反应蛋白和粪便钙卫蛋白呈中度相关,但与CD内镜严重程度不相关;所有患者报告结局均与铁、铁蛋白或维生素D水平不相关。

关键数值与推荐

  • UC和CD患者分别有160例(78.8%)和99例(85.3%)报告至少1项患者报告结局中度至重度损害(P=.18)。
  • UC和CD患者分别有89例(43.8%)和74例(63.8%)报告至少2项患者报告结局中度至重度损害(P<.01)。

临床怎么用

  • 作者认为,新诊断炎症性肠病患者存在显著患者报告疾病负担,强调临床实践中警惕性监测患者报告结局的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patient-reported outcomes (PROs) are pivotal in assessing treatment efficacy and estimating the burden of inflammatory bowel diseases (IBDs). We investigated PROs at the time of IBD diagnosis. METHODS: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ), IBD Disability Index (IBD-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and disease activity-related PROs were assessed in the Copenhagen IBD Inception Cohort, a prospective, population-based cohort of patients newly diagnosed with IBD between May 2021 and May 2023. RESULTS: A total of 203 ulcerative colitis (UC) and 116 Crohn's disease (CD) patients were recruited. At diagnosis, 160 (78.8%) and 99 (85.3%) patients with UC and CD, respectively, reported moderate-to-severe impairment in at least 1 PRO (P = .18), with 89 (43.8%) and 74 (63.8%), respectively, reporting moderate-to-severe impairment in at least 2 PROs (P < .01). Being female, the disease extent of UC, and extraintestinal manifestations were associated with impaired PROs. There were no differences found according to CD phenotype. FACIT-F, IBD-DI, and SIBDQ scores showed weak, but significant, correlations with the Mayo endoscopic score in UC, and the FACIT-F score with C-reactive protein. In CD, SIBDQ, IBD-DI, and FACIT-F correlated moderately with C-reactive protein and fecal calprotectin but not with the endoscopic severity of CD. None of the PROs correlated with iron, ferritin, or vitamin D levels. Among the most prevalent symptoms reported were fatigue, abdominal pain, urgency, and passing of blood in both CD and UC. CONCLUSIONS: We found a substantial patient-reported disease burden in newly diagnosed IBD, underscoring the importance of vigilant PRO monitoring in clinical practice.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Attauabi M, Madsen GR, Bendtsen F, et al. Multidimensional Patient-Reported Outcomes and Quality of Life at Diagnosis of IBD: A Population-Based Inception Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 39461459. doi:10.1016/j.cgh.2024.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。